<PAGE> 1
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
-------------------------
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): July 1, 1996
Biofield Corp.
- - --------------------------------------------------------------------------------
(Exact name of registrant as specified in its charter)
Delaware 0-27848 13-3703450
- - --------------------------------------------------------------------------------
(State or other jurisdiction of (Commission (I.R.S. Employer
incorporation or organization) File Number) Identification No.)
1225 Northmeadow Parkway Suite 120, Roswell, GA 30076
- - --------------------------------------------------------------------------------
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code: (770) 740-8180
----------------------------
Not Applicable
- - --------------------------------------------------------------------------------
(Former name or former address, if changed since last report)
<PAGE> 2
Item 5. Other Events
Biofield Corp. (the "Company"), pursuant to its Preferred Stock and
Warrant Purchase Agreement dated March 3, 1995 (the "Series C Agreement",
incorporated by reference to Exhibit 10.10 to the Company's Registration
Statement No. 333-00796), and as a result of the Company's plans to submit its
Pre-Market Approval Application ("PMA") for the Biofield Diagnostic System to
the United States Food and Drug Administration ("FDA") after June 30, 1996,
issued warrants to purchase 357,192 shares of Common Stock of the Company to
shareholders who are party to the Series C Agreement. Said warrants were
issued on July 1, 1996, have an exercise price of $9.18 per share, and expire
on March 3, 2000.
The Company is in the process of analyzing the data from its U.S.
Multi-center Study. The final results will be included in the PMA for the
Biofield Diagnostic System. As previously reported, the Company plans to
submit the PMA to the FDA later this year.
<PAGE> 3
Signatures
Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.
Biofield Corp.
Dated: July 3, 1996 By: /s/ KENNETH W. ANSTEY
--------------------------
Kenneth W. Anstey
President, Chief Executive
Officer and Director
